SYNthesis BioVentures

We believe that Australian research is among the best in the world, yet there is a market failure at the heart of the Australian biotech market. SYNthesis BioVentures manages a fund (SYNthesis Bioventures Fund I) focused on early stage therapeutics, investing in projects from discovery through preclinical proof of concept and IND-enabling studies. We invest in small molecule therapeutics, biologics, and cell and gene therapies for indications with significant unmet need. By investing in projects from inception through to pre-IPO, we intend to facilitate the continuity of capital from Australian academia to venture financing and through Australian capital markets.